Business
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.
Janssen will provide its proprietary antibodies for research, while Mersana will contribute its proprietary Dolasynthem platform to target cancers with large unmet medical needs.
Humira will begin to lose exclusivity in 2023, and numerous biosimilar competitors are waiting to break in on the drug’s lucrative market.
The global women’s health company took another step in its initiative to encourage healthcare equality for women by declaring March 8, International Women’s Day, an annual holiday.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Even as Novartis entertains the potential sale of Sandoz, the company is lauding growth in its biosimilars business that is expected to stabilize its future development.
In a new “Measuring the Return from Pharmaceutical Innovation” report by Deloitte’s Center for Health Solutions, returns from R&D innovation are up by 7% across the industry.
Pfizer announced that Dr. William Pao, M.D., Ph.D., will take on the role of executive vice president and chief development officer as of March 21.
OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.